Tiny study aims to Fine-Tune fungal drug dosing during plasma exchange

NCT ID NCT07532850

Not yet recruiting Knowledge-focused Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will look at how the antifungal drug liposomal amphotericin B behaves in 10 critically ill patients with severe fungal infections who are also receiving plasma exchange therapy. The goal is to understand how plasma exchange changes drug levels in the body, which could help doctors give the right dose. It is a small, early-stage study focused on gathering information, not testing a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liposomal amphotericin B
What this could lead to: If successful, this could help doctors personalize dosing of liposomal amphotericin B for patients on plasma exchange, improving treatment effectiveness.
What could go wrong: This is a very small, early-stage study with only 10 participants, so results may not apply broadly. It focuses on drug levels, not directly on curing the infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE FUNGAL INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Invasive Fungal Infections systemic mycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INVASIVE FUNGAL INFECTIONS

More trials for these conditions

Other studies related to the condition(s) this trial covers.